Navigation Links
Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
Date:6/12/2008

Program Supports Development of Strong Scientific Capacity in Latin America

WASHINGTON, June 12 /PRNewswire-USNewswire/ -- The Pew Charitable Trusts and the University of California at San Francisco (UCSF) announced today that 10 promising biomedical scientists have been named 2008 Pew Latin American Fellows in the Biomedical Sciences. Funded by Pew through a grant to UCSF, the highly competitive fellowship program offers talented young Latin American scientists $60,000 for a two-year training period. The award is administered by the sponsoring U.S. institution, which supplements the stipend with at least $5,000 a year and also provides medical benefits for the fellow. Following the two year fellowship, the Program will issue an additional $35,000 award to the sponsoring institution to purchase equipment and supplies for the fellow to establish a laboratory in his or her home country.

"Pew's Latin American Fellows Program gives these exemplary scientists the opportunity to further their knowledge, and it promotes exchange and collaboration between researchers in the United States and Latin America," said Rebecca W. Rimel, President and Chief Executive Officer of The Pew Charitable Trusts.

The Pew Latin American Fellows Program in the Biomedical Sciences was launched in 1991 to help develop a cadre of highly trained Latin American scientists who could stimulate and contribute to the growth of quality biomedical science and foster collaboration between scientists in Latin America and the U.S. Since 1991, the Trusts has invested more than $11 million to fund more than 150 fellows, close to 80 percent of whom have returned to their home countries. Applicants from all Central and South American countries are invited to apply, and selection is made by a distinguished national advisory committee chaired by Dr. Torsten N. Wiesel, president emeritus of Rockefeller University and a 1981 Nobel laureate in physiology or medicine.

The 2008 Pe
'/>"/>

SOURCE Pew Charitable Trusts
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
2. Monsantos Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America
3. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
4. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
5. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
6. White Paper Details New Techniques for Isolating, Identifying Anaerobic Bacteria and Organisms
7. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial
8. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
9. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
10. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
11. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ... developing novel mid- to late-stage cardiovascular drug candidates, ... in its first round of financing. The Series ... and Hercules Bioventures with participation from investors that ... pharmaceutical executive, Dr. Larry Hsu , the ...
(Date:8/28/2014)... August 28, 2014 Earlier this month, ... in partnership with the U.S. Air Force on ... The results indicated that this type of fuel made ... and will be important to America’s Eco friendly future. ... has a mandate to become independent of foreign oil ...
(Date:8/27/2014)... Lake City, Utah (PRWEB) August 27, 2014 ... construction that will expand its current Salt Lake City ... currently underway outside of Utah to ultimately create 1,000 ... next 20 years. , “Utah is home to ... of whom can be credited with Varian’s success in ...
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that ... in its catalogue: Global Biodegradable ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable ... are readily decomposed by the action of ... packaging in terms of raw materials, production ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced ... Officer of Alexion,Pharmaceuticals, will present at the William ... 9:10 a.m., local time (10:10 a.m., eastern) on,Thursday, ... Mr. Sinha,s remarks will be available live. You ...
... III study, consistent with landmark IRIS trial, which established Gleevec as standard ... of care, ... molecular responses ... of Gleevec may help optimize ...
... One of the Industry,s Largest eClinical ... ... (Nasdaq: PRXL ), a leading global biopharmaceutical services,organization, today ... company traded on the London Stock Exchange, ("ClinPhone"),have reached agreement ...
Cached Biology Technology:Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 2Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 3Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 4Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 6Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 7Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 8Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 9Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 10Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 11Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 12Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 13PAREXEL Reaches Agreement To Acquire ClinPhone 2PAREXEL Reaches Agreement To Acquire ClinPhone 3PAREXEL Reaches Agreement To Acquire ClinPhone 4PAREXEL Reaches Agreement To Acquire ClinPhone 5
(Date:8/28/2014)... MINNEAPOLIS/ST. PAUL (August 28, 2014) Researchers at the ... for facioscapulohumeral muscular dystrophy (FSHD) to be used for ... effectiveness of potential therapies for FSHD. , The research ... Cell Reports . , There is no treatment ... the most common type of muscular dystrophy. FSHD is ...
(Date:8/28/2014)... compounds that could positively impact the global ... possible, thanks to researchers in Penn State,s ... suppository made from the seaweed-derived food ingredient ... Tenofovir provides a woman-initiated, drug-delivery vehicle that ... transmitted infections during unprotected heterosexual intercourse, the ...
(Date:8/28/2014)... than 25 million kilometres of new roads will be ... slice into Earth,s last wildernesses, where they bring an ... , Now, an ambitious study has created a ,global ... try to balance the competing demands of development and ... ,environmental-values, layer that estimates that natural importance of ecosystems ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Japanese researchers have identified a key step in metabolic pathways ... the protein complex TORC 2 was published online in the ... activates a protein called Akt, which plays a crucial role ... of microbiology in the College of Biological Sciences at UC ...
... by Rice University bioengineers finds that the workhorse proteins that ... protein, called kinesin, is a two-legged molecular machine. Rice,s scientists ... both singly and in pairs, and they report this week ... together -- in part because they are so effective on ...
... One of the most frustrating problems faced by doctors who ... More than 38,000 people in the United States die ... are desperately needed. For almost three decades, scientists and ... is mutated in virtually all pancreatic cancers, making it an ...
Cached Biology News:Understanding diabetes at the molecular level 2'Prima donna' protein doesn't work well in pairs 2'Prima donna' protein doesn't work well in pairs 3UNC team discovers promising target for new pancreatic cancer treatments 2
... AVOID FREEZE/THAW CYCLES. An assay kit designed ... Western blotting. PARP is an enzyme implicated ... apoptosis, PARP is cleaved by caspase-3. Cleavage ... to 85 kDa is a hallmark of ...
... These handy dispensers save ... glasses, wipers, hats, and other ... benchtop storage bins for small ... and manufacturing. Clear acrylic. Many ...
... handy dispensers save space and ... hats, and other garb. They ... bins for small parts used ... Clear acrylic. Open-slot design for ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: